Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: the Survey of PatIents with treatment ResIstant hyperTension study.
Adrenergic beta-Antagonists
/ therapeutic use
Aged
Antihypertensive Agents
/ pharmacology
Blood Pressure
/ drug effects
Blood Pressure Determination
Blood Pressure Monitoring, Ambulatory
Calcium Channel Blockers
/ therapeutic use
Diuretics
/ therapeutic use
Drug Therapy, Combination
Female
Humans
Hypertension
/ drug therapy
Male
Middle Aged
Mineralocorticoid Receptor Antagonists
/ therapeutic use
Renin-Angiotensin System
/ drug effects
Retrospective Studies
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
pubmed:
16
8
2019
medline:
7
7
2020
entrez:
16
8
2019
Statut:
ppublish
Résumé
We evaluated the characteristics of patients with treatment-resistant hypertension (TRH) and the prevalence of TRH in a large multicountry sample of specialist tertiary centres. The Survey of PatIents with treatment ResIstant hyperTension (SPIRIT) study was a retrospective review of medical records of patients seen at tertiary centres located in Western Europe, Eastern Europe, North America, South America, Australia and Asia. Data on demographics, medical history and medication use were extracted from medical records. Prevalence and incidence of TRH were based upon estimated catchment populations. On thousand, five hundred and fifty-five patients from 76 centres were included, mostly from centres that specialize in hypertension (55%), cardiology (11%) or nephrology (19%). Mean age was 64, 60% were men, 62% were Caucasian, 36% had chronic kidney disease, 41% had diabetes, 12% were smokers and 31% had a previous cardiovascular event. Daytime and night-time ambulatory blood pressure (BP) was the most frequently used measurement for diagnosis (82%). Ninety-five percent of patients were prescribed diuretics, 93% an inhibitor of the renin-angiotensin system, 86% a calcium channel blocker, 74% a beta-blocker and 36% an aldosterone antagonist. The overall estimated mean incidence of TRH was 5.8 per 100 000 per year (ranging between 2.3 and 14.0 across regions) and the corresponding estimated mean prevalence of TRH was 23.9 per 100 000 (ranging between 7.6 and 90.5 across regions). Observed variation likely reflects real differences in patient characteristics and physician management practices across regions and specialities but may also reflect differences in patient selection and errors in estimation of catchment population across participating centres.
Identifiants
pubmed: 31415307
doi: 10.1097/HJH.0000000000002184
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Antihypertensive Agents
0
Calcium Channel Blockers
0
Diuretics
0
Mineralocorticoid Receptor Antagonists
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM